Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 in Papillary Renal Cell Cancer
NCT02019693Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2014
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capmatinib in papillary renal cell carcinoma (PRCC), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate up to 238 weeks. Started Jan 2014; status: completed.
02
Drugs
capmatinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT02019693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019693.